利法西明在小鼠模型中缓解了因伊利诺特干诱导的腹
Chengyi Huang1,2,3,4, Huiyin Lan1,3,4, Minghua Bai1,3,4
1Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
利法西明通过减少肠道炎症和维持屏障功能,有效地预防小鼠的虹素诱导腹. 这项研究表明,利法西明是一种有前途的保护剂,可以预防化疗副作用.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 氨酸是一种用于固体瘤的化疗药物.
- 氨酸的显著副作用是延迟发作的腹.
- 这项研究研究了利法西明对因虹膜素诱导的粘膜炎的保护作用.
研究的目的:
- 在小鼠模型中证实利法西明对因氨基酸诱导的腹和粘膜炎的保护作用.
- 为了评估利法西明对肠道微生物群和屏障功能的影响,在治疗后.
主要方法:
- 小鼠接受了 irinotcan,rifaximin 或其组合的治疗.
- 监测了腹,体重和肠道组织.
- 分析了肠道微生物群组成,细菌酶活性和肠道透性.
主要成果:
- 利法西明可降低氨酸诱导的腹的频率和严重程度.
- 利法西明抑制了SN38暴露和细菌β-葡萄糖酶活性.
- 利法西明缓解了肠道炎症,保护了上皮损伤,并维持了肠道屏障功能.
- 利法西明调节了肠道微生物群的组成,而不会引起失调.
结论:
- 预防性服用利法西明是一种可行的策略,可以减轻因虹素素诱导的腹.
- 利法西明显示出作为抗化疗诱导的胃肠道毒性保护剂的潜力.
更多相关视频
08:02Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence
Published on: March 12, 2020
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
